Soft furnishings for aircrafts successfully tested against SARS-CoV-2
STOCKHOLM, Jan. 28, 2021 /PRNewswire/
British Addmaster Holdings Limited is since January 8, 2021, a wholly owned subsidiary of Polygiene with specialist skills within antimicrobial technology and hard surfaces. The company has a range of products for this kind of applications, found in consumer products, public spaces as well as in hospital environments and more.
MGR Foamtex Ltd, world-leader in the design, development and manufacture of advanced passenger upholstery systems for Premium cabin seating, has announced that its advanced antimicrobial MGRSafeWall product protection system has been successfully tested against SARS-CoV-2, the virus that causes COVID-19, using Addmaster Biomaster antimicrobial technology.
Nexstim Oyj: German University Hospital Orders Nexstim NBS System with NexSpeech
German University Hospital Orders Nexstim NBS System with NexSpeech
Nexstim Plc (NXTMH:HEX, NXTMS:STO) ( Nexstim or Company ) announces that a University Hospital in Germany has ordered a Nexstim NBS System with NexSpeech.
The hospital is a new customer for Nexstim. The NBS System with NexSpeech will be used for neuroscientific research and diagnostics.
Nexstim NBS System uses the unique SmartFocus navigated transcranial magnetic stimulation (nTMS) technology which enables accurate and precise stimulation of the brain. SmartFocus nTMS mapping conducted with NBS system is a non-invasive and accessible way of diagnosing the tumour s or other lesion s location. In addition to motor mapping, NBS System can be used also for locating language eloquent areas when used together with NexSpeech module.
1 Introduction
1.1 Listings of Special Purpose Acquisition Companies
( SPACs ) have been popular in the US
for a long time, including in the last decade. Despite high
activity in the Swedish IPO market, with record breaking numbers of
transaction and great demand for new IPOs (also for companies that
are in early phase and not yet profitable), SPACs have yet to be
introduced in Sweden. We have, however, noted an increased interest
from clients around the possibility to launch a Swedish SPAC and in
this memorandum, we outline the basic concept of a SPAC and
describe key issues/hurdles to be considered in relation to Swedish
Polygiene s subsidiary Addmaster contributes to the CAT® launch of the first fully antimicrobial mobile phone
News provided by
Share this article
STOCKHOLM, Jan. 22, 2021 /PRNewswire/
British Addmaster Holdings Limited is since January 8, 2021, a wholly-owned subsidiary of Polygiene with specialist skills within antimicrobial technology and hard surfaces. The company has a range of products for this kind of applications, found in consumer products, public spaces as well as in hospital environments and more.
According to a
press release published by Addmaster January 21:
The UK-based Bullitt Group, makers of military-grade smartphones and the global licensee for CAT® phones, has launched the first fully antimicrobial mobile phone - the CAT S42. The entry-level Android smartphone with antimicrobial protection is designed for military use but is now also available to the public.
Nanoform s Clinical Study Indicates Positive Interim Results
News provided by
Share this article
Share this article
HELSINKI, Jan. 22, 2021 /PRNewswire/ Nanoform Finland Plc ( Nanoform ), an innovative nanoparticle medicine enabling company, today announced positive interim results from its clinical study. The faster absorption data implies that small particles can indeed be powerful.
Nanoform has received interim study results related to its Phase 1, Single-Centre, Part Crossover, Open-Label, Partially-Randomised Study Designed to Evaluate the Pharmacokinetic (PK) Profile of Piroxicam following Administration of Nanoformed Oral Immediate Release (IR) Piroxicam Tablet and an IR Reference Product in Healthy Subjects (UNICORN). These interim results are based on the first cohort of twelve healthy volunteers dosed in December 2020 at Quotient Sciences facilities in Nottingham, UK. Final results of the study are expected before the end of Q2 2021, as previously announced.